JONATHAN FAWCETT, Ph.D.
Executive Director, Clinical Development
Jonathan joins Sutro with 20 years of experience in drug development both in pharma and as an investigator in his clinician-scientist career. Prior to moving to the US in early 2019, he lead a large clinical team in liver transplantation and surgery in Australia and was active in the Australasian GI Trials Group. His clinical research focussed on donor organ preservation, primary/metastatic liver cancer and pancreatic cancer. At Exelixis, Jonathan lead a Phase 3 study in 1L advanced HCC before transitioning to early stage clinical development, working on adc and immuno-oncology assets from IND preparation through early phase clinical studies, including two Tissue Factor-targeted adcs. Originally Canadian, he was schooled in the UK, graduated in medicine with 1st class honours from the University of Newcastle upon Tyne. He received a PhD in molecular biology from the University of Oxford for his graduate research in cell adhesion and recombinant protein synthesis at the Institute of Molecular Medicine.